Adagene Inc. announced on July 1, 2025, that Sanofi has agreed to make a strategic investment of up to US$25 million in the company. These proceeds are earmarked to fund Adagene's research and development activities, specifically including the clinical development of muzastotug (ADG126), an anti-CTLA-4 SAFEbody, through a randomized Phase 2 trial in microsatellite stable colorectal cancer (MSS CRC). This investment is expected to extend Adagene's cash runway into 2027.
In addition to the investment, Sanofi has exercised its option to select a third SAFEbody discovery program, utilizing Adagene’s proprietary masking technology and antibody engineering expertise. This exercise includes an option fee, along with potential milestone and royalty payments as per their 2022 partnership agreement. Sanofi will also sponsor a Phase 1/2 clinical trial to evaluate ADG126 in combination with other anticancer therapies in over 100 patients with advanced solid tumors, while Adagene retains worldwide commercial rights to muzastotug.
The expanded partnership and strategic investment from Sanofi underscore the significant external validation of Adagene's SAFEbody platform and the clinical proof of concept for ADG126. A Sanofi representative will join Adagene’s Scientific Advisory Board, further integrating expertise and reinforcing the collaborative vision for ADG126 in advanced solid tumors.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.